Gilead 2017 guidance disappoints, as 4th-qtr sales and profits fall

8 February 2017
2019_biotech_test_vial_discovery_big

US biotech major Gilead Sciences (Nasdaq: GILD) recorded sales of $7.32 billion for the fourth-quarter of 2016, down 14.2% from $8.41 billion in the like year-earlier period but just beating analysts’ expectations of $7.2 billion.

Net income reached $3.12 billion, down 33.6% versus $4.68 billion in the fourth quarter of the previous year. Diluted earnings per share were $2.34 versus $3.19 and non-generally accepted accounting principles (GAAP) EPS at $2.70 versus $3.32.

Gilead shares fell 5.32% to $73.13 in after-hours trading on Tuesday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology